贝瑞基因：公司产前检测市场已达成较好的商业效应，但在孕前和新生儿市场还处于起步阶段

Core Viewpoint - The company is focusing on the reproductive health sector and aims to expand its business despite ongoing financial challenges and significant credit impairment losses [2]. Group 1: Business Focus and Strategy - The company has achieved good commercial effects in the prenatal testing market but recognizes that the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [2]. - The company plans to leverage artificial intelligence and its years of experience in third-generation sequencing technology to offer complex genetic testing services in more areas [2]. - Future plans include providing more health services directly to end consumers (C-end) by integrating clinical medical data [2]. Group 2: Shareholder and Control Issues - The company stated that the recent judicial auction of shares by major shareholders will not affect its business development [2].